The way we bring new medicines to life is changing. Regulators, scientists and healthcare professionals are working together to ensure access to new medicines and technologies is accelerated. Scientists will be delivering a wave of innovation for patients, from immunotherapies to fight cancer and cell therapies for genetic diseases to new dementia treatments, with UK R&D leading the way in many of these areas. Personalised medicines will also begin to play an increasing role. This may change the way we care for people and what our healthcare systems look like. How will society pay for this progress?
Patients are increasingly at the heart of how medicines are developed and used. Patients are becoming more involved in clinical trials. Patients can play a bigger role in identifying the outcomes that matter most to them. They also have a big say in how their data is used and managed in the right way.
At the same time, transparency about how medicines are developed is increasing. Trust and reputation are under the microscope – we take that seriously and are making good progress.
The future of healthcare is an exciting one. We’re tackling increasingly rarer diseases, whilst also delivering improved healthcare and prevention in an ever-ageing population. Cost and affordability of new medicines are also big challenges. We are working with the UK Government and the NHS to find the right solutions for all: patients, the NHS and the UK economy. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry provides progress and hope, so we can help patients live longer, healthier and productive lives.
Find out more about the work of our industry with up-to-date stats and facts about everything from clinical trials to R&D expenditure via the links below.
Medicines and vaccines have helped deliver incredible improvements in patient health. History shows us the great advances we have made – today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
Innovation in medicines above all requires commitment – commitment of time, resources and continuous endeavour – because this is one of the most uncertain of investments. Innovation also requires persistence, because success in developing new medicines does often not come at the first try.
Globally, the pharmaceutical industry undertakes the greatest share of clinical research trials, and this investment makes possible the provision of innovative, novel treatments for a wide range of disease and ill-health as well as for prevention. In addition, the investment in clinical research provides substantial benefits to the health systems and economies in which it is undertaken.